Announcement • Jul 29
Rocket Doctor AI Inc. announced that it expects to receive CAD 2 million in funding Rocket Doctor AI Inc. to announce a non-brokered private placement of unsecured convertible debentures in the amount of CAD 1,000 each in the aggregate principal amount of up to CAD 2,000,000 on July 28, 2026. The Debentures will bear interest from the date of issuance at a rate of 12.0% per annum, calculated and payable on maturity which is 12 months following the issuance of the Debentures. The principal amount of the Debentures, together with any accrued and unpaid interest, may be converted, in whole or in part at the election of the holder, into units of the Company at a conversion price of CAD 0.70 per Unit on the earlier of: (i) the business day immediately preceding the Maturity Date; and (ii) the business day immediately preceding the date fixed for redemption of the Debentures by the Company, if any, subject to the terms therein. Each Unit will consist of one common share in the capital of the Company and one transferable Share purchase warrant (a “Warrant”), with each Warrant being exercisable into one Share (a “Warrant Share”) at an exercise price of CAD 0.75 per Warrant Share for a period of 12 months from the date of issuance pursuant to the terms therein. The Warrant Expiry Date may be accelerated in the event the Shares trade on the CSE at CAD 0.75 or more per Common Share for any 10 consecutive trading days, and, upon delivery of a notice to the holder, the Warrant Expiry Date will be accelerated to 5:00pm on the date that is 10 calendar days from the date of delivery of an acceleration notice to the holder. Closing of the Offering is subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals, including that of the CSE. The securities issued in connection with the Offering will be subject to applicable statutory hold periods imposed under applicable securities legislation. The Offering is not subject to a minimum aggregate amount of subscriptions and may close in one or more tranches. The Company anticipates paying finders' fees to eligible parties who have assisted in introducing subscribers to the Offering. Any finders' fees payable will be in accordance with the policies of the CSE. Announcement • Jul 07
Rocket Doctor Ai Inc. Announces CFO Changes Rocket Doctor AI Inc. had appointed Mr. Andrew Lau, CPA, CA as Chief Financial Officer, effective July 6, 2026. Mr. Lau brought over 18 years of capital markets, corporate finance, and public company experience to Rocket Doctor AI. Throughout his career, he had held executive finance leadership roles with high-growth technology and life sciences companies, where he had led corporate finance, treasury, financial reporting, corporate development, and public company initiatives. Mr. Lau began his career with Deloitte LLP, where he earned his Chartered Professional Accountant designation, before joining RBC Capital Markets as an investment banker specializing in M&A and equity financing transactions. Over the course of his career, he had advised on and executed more than $700 million in M&A and capital markets transactions and had played a key role in helping emerging growth companies scale, strengthen their financial operations, and access the public markets. Mr. Lau replaced Mr. Chris Cherry, who stepped down as Interim CFO to return to his role as Chair of the Audit Committee while continuing his service as a director. Live News • Jul 01
Rocket Doctor AI Secures First US Value-Based Care Deal Expanding Access for 5 Million Members Rocket Doctor AI has entered its first value-based primary care provider agreement in the US with a California independent physician association, expanding its in-network coverage to more than 5 million patients across multiple payer types under a recurring per-member-per-month model.
The deal gives Rocket Doctor AI a foothold in California and shifts a portion of its business toward value-based care, with an emphasis on continuity of care, preventive health and long-term patient outcomes, which could influence how revenue is earned and recognized.
Rocket Doctor AI shares last traded at CA$0.60, with the stock down 26.8% year to date.
This move introduces a recurring revenue framework tied to patient panels rather than one-off visits. This structure can change both growth potential and execution risk, particularly around care quality, cost control and relationship management with payers and physicians. 
